Pharmaceutical PV DIV - FSB

The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,255.34 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. This delivery order, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, represents one of numerous purchase orders DMS Pharmaceutical Group has received under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The award carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. DMS Pharmaceutical Group was awarded a single-award Indefinite Delivery Contract under the PPV-G GEN V on November 13, 2025, with a $499.999 billion ceiling and a completion date of December 31, 2036, positioning the company as a regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy.

Under this delivery order and the underlying indefinite delivery contract, DMS Pharmaceutical Group supplies a comprehensive range of pharmaceutical products to the Department of Defense's military healthcare system, including branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, and specialty pharmaceuticals. The company's product portfolio encompasses critical medications such as oncology treatments, immunosuppressants, emergency medications including epinephrine auto-injectors and naloxone, specialty surgical products, and routine pharmaceuticals spanning antibiotics, antivirals, and pain management drugs. The IDC authorizes DLA to issue firm fixed-price delivery orders for pharmaceutical products supporting recurring medical supply needs of military healthcare facilities worldwide, with the contract structured to serve as a critical pharmaceutical supplier for Department of Defense healthcare operations globally.